CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
ConditionClassical Hodgkin Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age6-29
SponsorNew York Medical College
About this trial
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Eligibility criteria
Qualifiers
Age between ≥ 6 and ≤ 29.99 years at the time of consent.
Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.
Disqualifiers
not meeting the inclusion criteria
Trial design
Treatments tested in this trial
- CD30 CAR T-cell
Treatment groups
21 Participants
are divided into 1 treatment groupSponsors and collaborators
New York Medical College
Lead sponsor
University of North Carolina
Collaborator
Source ClinicalTrials.gov